Chamber
commons
Stage
2nd Reading
Introduced
Sep 18, 2025
Progress
This bill removes natural health products from the same regulatory oversight applied to drugs and therapeutic products under the Food and Drugs Act.
Key Changes
- Removes natural health products from the definition of 'therapeutic product' under the Food and Drugs Act
- Exempts natural health products from the stricter drug monitoring regime that was applied to them starting in 2023
- Repeals two specific sections of the Food and Drugs Act that extended therapeutic product oversight to natural health products
- Cancels any ongoing or potential legal proceedings against natural health product companies for offences committed under the 2023 rules
- Maintains an exception: nicotine-containing natural health products used in nicotine replacement therapy remain classified as therapeutic products
Gotchas
- The transitional provision retroactively shields companies from prosecution for offences committed under rules introduced in 2023, which may raise concerns about accountability for any regulatory violations during that period
- Nicotine replacement therapy products (e.g., nicotine patches or gums classified as natural health products) are specifically kept under the therapeutic product framework, creating a carve-out within the exemption
- This bill effectively reverses a regulatory tightening introduced through the 2023 federal budget, meaning the change was originally made without a standalone bill and is now being undone the same way — through a private member's bill
- Natural health products would continue to be regulated, but under the less stringent Natural Health Products Regulations rather than the therapeutic product monitoring regime
Who's Affected
- Natural health product manufacturers and distributors
- Retailers selling vitamins, supplements, and herbal remedies
- Consumers who use natural health products
- Health Canada regulators
- Companies that may have faced legal proceedings under the 2023 rules
Vibes
0 responses
Gotchas
- The transitional provision retroactively shields companies from prosecution for offences committed under rules introduced in 2023, which may raise concerns about accountability for any regulatory violations during that period
- Nicotine replacement therapy products (e.g., nicotine patches or gums classified as natural health products) are specifically kept under the therapeutic product framework, creating a carve-out within the exemption
- This bill effectively reverses a regulatory tightening introduced through the 2023 federal budget, meaning the change was originally made without a standalone bill and is now being undone the same way — through a private member's bill
- Natural health products would continue to be regulated, but under the less stringent Natural Health Products Regulations rather than the therapeutic product monitoring regime
Summary
Bill C-224 amends the Food and Drugs Act to clarify that natural health products (like vitamins, herbal remedies, and supplements) are not considered 'therapeutic products' under the law. This means they would no longer be subject to the stricter monitoring and oversight rules that apply to pharmaceutical drugs and medical devices. The bill was introduced in response to changes made by the Budget Implementation Act, 2023, No. 1, which brought natural health products under the therapeutic product framework. This bill would reverse that change, returning natural health products to a separate, lighter regulatory category under the Natural Health Products Regulations. The bill affects consumers, manufacturers, and retailers of natural health products in Canada. It also includes a transitional provision that stops or cancels any legal proceedings that were started against natural health product companies for offences that occurred after the 2023 budget law came into force and before this new bill takes effect.
Automatically generated from bill text using Claude
Vibes
0 responses